Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | GRIA1 | P42261 | 1/20 | 1.00 |
| ▸ | GRIA2 | P42262 | 1/20 | 1.00 |
| ▸ | GRIA3 | P42263 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | GRIA4 | P48058 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclothiazide SCHEMBL1362539 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL121096 | 1.00 | LMNA (1.00) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL22824000 | 0.96 | LMNA (0.92) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL21587525 | 0.92 | LMNA (0.85) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28279779 | 0.89 | LMNA (0.78) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28086726 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL28086372 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL17471612 | 0.87 | LMNA (0.76) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| Cyclothiazide SCHEMBL7614349 | 0.86 | LMNA (0.73) | LMNACYP3A4KMT2ATHRBCHRM1 | |
| SCHEMBL19166751 | 0.84 | LMNA (0.73) | LMNACYP3A4KMT2ATHRBCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | LMNA 4525/4885CYP3A4 4067/4885KMT2A 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.